It has been widely known that human epidermal growth factor receptor 2 (HER2) inhibitors exhibit distinct antitumor responses against HER2-positive breast cancer. To date, Lapatinib (Tykerb®) has been approved by the U.S. Food and Drug Administration (FDA) as a reversible HER2 inhibitor for ...
[11]Mougalian SS,Soulos PR,Killelea BK,et al.Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.Cancer.2015;121:2544–2552. [12]Chen S,Liang Y,Feng Z,et al.Efficacy and safety o...
[10]Cai, Z., Wang, J., Li, Y., et al. (2023). Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Science China. Life sciences, 66(1), 94–109. [11]Andrikopoulou, A.,...
[4]Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinasedomain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors[J]. Cancer Cell, 2006, 10(1):25...
1.Singla H, Munshi A, Banipal R P S, et al. Recent updates on the therapeutic potential of HER2 tyrosine kinase inhibitors for the treatment of breast cancer[J]. Current Cancer Drug Targets, 2018, 18(4): 306-327. 2.Lukong K E. Understanding breast cancer–The long and winding road[...
[1]Schlam I,Swain SM. HER2-positive breast cancer and tyrosine kinaseinhibitors: the time is now[J]. NPJ Breast Cancer ,2021 ,7(1):56 [2]von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W...
5.Arteaga C L, Sliwkowski M X, Osborne C K, et al. Treatment of HER2-positive breast cancer: current status and future perspectives[J]. Nature Reviews Clinical Oncology, 2012, 9(1): 16. 6.Hynes N E, Lane H A. ERBB receptors and cancer: the complexity of targeted inhibitors[J]. ...
dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic breast cancer (MBC) ...
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-354. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. ...
et al. Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nat Cancer 3, 821–836 (2022). https://doi.org/10.1038/s43018-022-00412-y Download citation Received27 July 2021 Accepted16 June 2022...